127 related articles for article (PubMed ID: 34677236)
1. Clinical Outcomes from Dose-Reduced Radiotherapy to the Prostate in Elderly Patients with Localized Prostate Cancer.
Samson N; Khanolkar RA; Quirk S; Quon H; Roumeliotis M; Balogh A; Sia M; Thind K; Husain S; Martell K
Curr Oncol; 2021 Sep; 28(5):3729-3737. PubMed ID: 34677236
[TBL] [Abstract][Full Text] [Related]
2. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
4. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
Sargos P; Mottet N; Bellera C; Richaud P
BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
[TBL] [Abstract][Full Text] [Related]
5. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
6. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
[TBL] [Abstract][Full Text] [Related]
7. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
9. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
[TBL] [Abstract][Full Text] [Related]
11. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
Kim YJ; Ahn H; Kim CS; Kim YS
Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
13. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.
Wilcox SW; Aherne NJ; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):125-33. PubMed ID: 25588566
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
[TBL] [Abstract][Full Text] [Related]
15. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
16. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
17. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
[TBL] [Abstract][Full Text] [Related]
19. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.
Ghadjar P; Oesch SL; Rentsch CA; Isaak B; Cihoric N; Manser P; Thalmann GN; Aebersold DM
Radiat Oncol; 2014 May; 9():122. PubMed ID: 24885327
[TBL] [Abstract][Full Text] [Related]
20. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.
Hou WH; Huang CY; Wang CC; Lan KH; Chen CH; Yu HJ; Liu SP; Lai MK; Pu YS; Cheng JC
Asian J Androl; 2017; 19(5):596-601. PubMed ID: 27506334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
